Annexon Biosciences

Annexon Biosciences is a biotechnology company focused on developing therapies to treat autoimmune, neurodegenerative, and ophthalmic diseases. The company specializes in targeting the C1q protein, a key initiator in the classical complement pathway, to block damaging immune responses and halt the progression of complement-driven diseases. Their research and development efforts aim to deliver transformative treatments for conditions affecting the body, brain, and eye. Annexon recently announced positive results from a Phase 3 trial of their C1q-blocking antibody ANX005 for treating Guillain-Barré syndrome.